Well, this is the final trial, which means that at the end of the day, they will submit it for approval (or they won’t, depending on the outcome of the trial).
As for what they are looking for:
– Does the vaccine work? (they already know it, but the trial is big, so they can get a% for its efficiency)
– How effective is it at producing antibodies?
– Side effects (which ones, what severity and incidence rate)
– And I guess they are checking how long they can detect antibodies in vaccinated people.
The trial runs until October 2022, so 2 years plus change – this date is also subject to change, if the data is inconclusive it can extend it, or if the data is bad it might just put end of the trial (if they see any serious side effects, which could easily shorten the trial.
In any case, this is unlikely to hit the market before 2023 (regulatory approval takes time, even if rushed).